Evaluation of therapeutic efficacy of ²¹¹At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer.

ABSTRACT:

Introduction

Antibodies labeled with alpha-emitter astatine-211 have previously shown effective in intraperitoneal (i.p.) treatments of ovarian cancer. In the present work we explore the use of investigational farletuzumab, aimed at the folate receptor alpha. The aim was to evaluate the biodistribution and therapeutic effect of ²¹¹At-farletuzumab in in-vitro and in-vivo experiments and, using models for radiation dosimetry, to translate the findings to expected clinical result. The activity concentration used for therapy in mice (170 kBq/mL) was chosen to be in agreement with an activity concentration that is anticipated to be clinically relevant in patients (200 MBq/L).

Methods

For biodistribution, using intravenous injections and mice carrying subcutaneous (s.c.

SUBMITTER: Palm S 

PROVIDER: S-EPMC7522120 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature